Duloxetine reduces chemo-induced neuropathy
Published On: 4/2/2013 3:00:00 PM
BY MARY ANN MOON
IMNG Medical News
http://www.imng.com
Breaking News
A 5-week course of daily oral duloxetine reduced pain and
improved function and quality of life for patients with
chemotherapy-induced peripheral neuropathy, according to a report
in the April 3 issue of JAMA.
Duloxetine's effects on chemotherapy-induced peripheral
neuropathic pain were measured in a randomized, double-blind,
placebo-controlled, crossover clinical trial involving 231 cancer
patients aged 25 years and older who had been treated with platinum
or taxane agents. Study subjects were approximately twice as likely
to experience a 30% reduction in pain while taking duloxetine than
while taking placebo and were 2.4 times more likely to experience a
50% reduction in pain, said Ellen M. Lavoie Smith, Ph.D., of the
University of Michigan School of Nursing, Ann Arbor, and her
associates. The data were presented at the 2012 annual meeting
of the American Society of Clinical Oncology.
Patients also reported better daily functioning with duloxetine,
compared with placebo, including improved scores on measures
assessing numbness, tingling, or discomfort of the hands or feet;
tinnitus or difficulty hearing; joint pain; muscle cramps and
weakness; and difficulty walking, dressing, or feeling small
objects in the hands. Pain-related quality of life also improved to
a greater degree with duloxetine (mean change of 2.44 points out of
44 possible points on the Functional Assessment of Cancer Treatment,
Gynecologic Oncology Group Neurotoxicity subscale) than with placebo (mean change of
0.87 points).
There were no hematologic or grade 4 adverse events. Mild
adverse events were reported by 16% during duloxetine treatment and
27% during placebo treatment, and moderate adverse effects were
reported by 7% and 3%, respectively. These included fatigue,
insomnia, and nausea in both patient groups, the investigators said
(JAMA 2013;309:1359-67).
This study was supported by the National Cancer Institute and
the Alliance Statistics and Data Center. Study drugs and placebo
were supplied by Eli Lilly. Dr. Smith reported no conflicts of
interest, and one of her associates reported ties to Genentech.
tor@frontlinemedcom.com
Subject Codes:
top_stories; oncology; pain;